Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.52 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.37 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.37 |
| ▸ | GSTP1 known ✓ | P09211 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.32 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10785895 | 1.00 | PTPRC (0.52) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| SCHEMBL27552426 | 0.98 | PTPRC (0.53) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| SCHEMBL448680 | 0.98 | PTPRC (0.53) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| SCHEMBL146910 | 0.98 | PTPRC (0.53) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| SCHEMBL29391697 | 0.98 | PTPRC (0.53) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| Hydrochloric Acid SCHEMBL27713616 | 0.96 | PTPRC (0.55) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| Hydrochloric Acid SCHEMBL29415866 | 0.96 | PTPRC (0.55) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| Anthracene SCHEMBL27939488 | 0.96 | PTPRC (0.55) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| Hydrochloric Acid SCHEMBL30337382 | 0.94 | PTPRC (0.53) | PTPRCALDH1A1HSD17B10HPGDCES1 | |
| SCHEMBL1118356 | 0.94 | PTPRC (0.57) | PTPRCALDH1A1HSD17B10HPGDCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12521386-B2 | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509468-B2 | Quindoline compounds and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-09-04 | — | — | US | disclosed |
| US-20250189527-A1 | COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE | DUKE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CATALENT PHARMA SOLUTIONS, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-18 | — | — | US | disclosed |
| US-11944626-B2 | Small molecule inhibitors of ALDH and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-04-02 | — | — | US | disclosed |
| US-20060084647-A1 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-04-20 | — | — | US | disclosed |
| US-20060078903-A1 | Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2006-04-13 | — | — | US | disclosed |
| US-20050288239-A1 | Anticancer glycoside compounds | NORTHWESTERN UNIVERSITY (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050232927-A1 | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050234135-A1 | Gossypol co-crystals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2005-10-20 | — | — | US | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-1423105-A2 | COMBINATIONS OF DMXAA AND OTHER ANTI-CANCER AGENTS | Cancer Research Technology Limited (GB) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003099296-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003020259-A2 | COMBINATIONS OF DMXAA AND OTHER ANTI-CANCER AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | BCHE 3225/4885ACHE 3889/4885MAOA 3138/4885 |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | HSPA5, HSPA2, PSMG3 | BCHE 4732/4885ACHE 3780/4885MAOA 4847/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | BCHE 4767/4885ACHE 4848/4885MAOA 3112/4885 |
| US-20050234135-A1 | Gossypol co-crystals and the use thereof | BAX, BCL2, CASP8 | BCHE 2973/4885ACHE 4862/4885MAOA 4799/4885 |
| US-12509468-B2 | Quindoline compounds and uses thereof | TPD52L2, BRDT, RECQL | BCHE 3444/4885ACHE 1819/4885MAOA 4390/4885 |
| US-20060084647-A1 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | BCL2, BAD, BCL2L1 | BCHE 4308/4885ACHE 4860/4885MAOA 4238/4885 |
| US-11944626-B2 | Small molecule inhibitors of ALDH and uses thereof | ALDH2, ALDH1A1, ALDH3A1 | BCHE 3230/4885ACHE 2856/4885MAOA 1254/4885 |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | SIRT6, SIRT2, SIRT1 | BCHE 3927/4885ACHE 1554/4885MAOA 3442/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | BCHE 4380/4885ACHE 4690/4885MAOA 4830/4885 |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | RNASE1, RNASEL, RNASEH1 | BCHE 1499/4885ACHE 3796/4885MAOA 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.